Peter Huang

Peter Huang, Ph.D., joined Zai Lab in November 2022 as Chief Scientific Officer, leading the company’s discovery efforts and translational medicine.

Prior to joining Zai Lab, Dr. Huang was the Senior Vice President of Discovery Research for Zentalis Pharmaceuticals, overseeing their drug portfolio and pipeline, building their discovery platform, leading discovery for multiple new clinical candidates, and overseeing translational research to support clinical development. Before joining Zentalis, he worked at Pfizer, Inc. as one of their oncology chemistry designers and focused on the discovery of small-molecule drugs. Dr. Huang was the key inventor of a number of clinical compounds, including lorlatinib, an anaplastic lymphoma kinase inhibitor (ALKi), which was approved by the U.S. Food and Drug Administration in 2018.

Dr. Huang was an honoree for the 2021 Heroes of Chemistry from the American Chemistry Society. He received his Ph.D. in organic chemistry from Iowa State University and completed his postdoctoral fellowship at The University of Chicago.